Strategy Inc. performed a business analysis for several of our biologic emerging technologies delivering a US market strategy. The due diligence with targeted key opinion leaders in a cross section of clinical subspecialties provided valuable perspective for market segments under consideration. Strategy Inc. also executed several competitive business analyses that included a pricing strategy to help define the US market opportunity for our technologies. Strategy Inc. consistently delivers very precise and strategic work, and we continue to design our US strategy with their insight.” Sylvain Picot, Président Directeur Général & Patricia Forest, PhD, Directrice Générale, Déléguée et Directrice Scientifique

Biom’Up, located in Lyon France and founded in 2005, develops, manufacturers and markets innovative implantable medical products based on biopolymers, primarily collagen. Based on continuing and iterative clinical input, the products are designed for general, cardiothoracic, maxillofacial, spinal and orthopedic surgery.